{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:24:59Z","timestamp":1770913499943,"version":"3.50.1"},"reference-count":46,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15062","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T11:46:06Z","timestamp":1745840766000},"page":"1-13","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety outcomes of emerging EGFR\u2011TKIs for patients with non\u2011small cell lung cancer with EGFR exon 20 insertion mutations: A systematic review and meta\u2011analysis"],"prefix":"10.3892","volume":"29","author":[{"given":"Kang","family":"Xie","sequence":"first","affiliation":[{"name":"Precision Medicine Centre, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Precision Medicine Centre, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Precision Medicine Centre, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhujun","family":"Deng","sequence":"additional","affiliation":[{"name":"Precision Medicine Centre, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiongxia","family":"Hu","sequence":"additional","affiliation":[{"name":"Precision Medicine Centre, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denian","family":"Wang","sequence":"additional","affiliation":[{"name":"Precision Medicine Centre, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"key20250513102207_b1-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"103009","DOI":"10.1016\/j.critrevonc.2020.103009","article-title":"Immunotherapy as a second-line or later treatment modality for advanced non-small cell lung cancer: A review of safety and efficacy","volume":"152","author":"Geraci","year":"2020","journal-title":"Crit Revi Oncol Hematol"},{"key":"key20250513102207_b2-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/ph13100273","article-title":"Epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC)","volume":"13","author":"O'Leary","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"key20250513102207_b3-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-15-2266","article-title":"FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer","volume":"22","author":"Kazandjian","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key20250513102207_b4-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1634\/theoncologist.2014-0089","article-title":"U.S. Food and drug administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations","volume":"19","author":"Khozin","year":"2014","journal-title":"Oncologist"},{"key":"key20250513102207_b5-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s40259-022-00556-4","article-title":"Non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: Diagnosis and treatment options","volume":"36","author":"Brazel","year":"2022","journal-title":"BioDrugs"},{"key":"key20250513102207_b6-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"e0247620","DOI":"10.1371\/journal.pone.0247620","article-title":"Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review","volume":"16","author":"Burnett","year":"2021","journal-title":"PLoS One"},{"key":"key20250513102207_b7-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.lungcan.2020.11.027","article-title":"Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations","volume":"152","author":"Yang","year":"2021","journal-title":"Lung Cancer"},{"key":"key20250513102207_b8-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/1078-0432.CCR-22-2072","article-title":"FDA approval summary: Mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations","volume":"29","author":"Duke","year":"2023","journal-title":"Clin Cancer Res"},{"key":"key20250513102207_b9-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/2159-8290.CD-20-1683","article-title":"Mobocertinib (TAK-788): A targeted inhibitor of EGFR exon 20 insertion mutants in non-small cell lung cancer","volume":"11","author":"Gonzalvez","year":"2021","journal-title":"Cancer Discov"},{"key":"key20250513102207_b10-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"e214761","DOI":"10.1001\/jamaoncol.2021.4761","article-title":"Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: A phase 1\/2 open-label nonrandomized clinical trial","volume":"7","author":"Zhou","year":"2021","journal-title":"JAMA Oncol"},{"key":"key20250513102207_b11-ol-29-6-15062","article-title":"FDA and takeda to withdraw mobocertinib for EGFR Exon20+ NSCLC","author":"Sava","year":"2023","journal-title":"Targeted Oncology"},{"key":"key20250513102207_b12-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/2159-8290.CD-21-1615","article-title":"Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations","volume":"12","author":"Wang","year":"2022","journal-title":"Cancer Discov"},{"key":"key20250513102207_b13-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-2600(20)30455-0","article-title":"Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: A phase 2b, multicentre, single-arm, open-label study","volume":"9","author":"Shi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"key20250513102207_b14-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"key20250513102207_b15-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20250513102207_b16-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"key20250513102207_b17-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"key20250513102207_b18-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12815","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"key20250513102207_b19-ol-29-6-15062","article-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023)","author":"Higgins","year":"2023"},{"key":"key20250513102207_b20-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: Initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20250513102207_b21-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"S1304","DOI":"10.1016\/j.annonc.2023.10.060","article-title":"LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study","volume":"34","author":"Girard","year":"2023","journal-title":"Ann Oncol"},{"key":"key20250513102207_b22-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.jtho.2022.06.002","article-title":"Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M-mutated NSCLC that had progressed after prior EGFR tyrosine kinase inhibitor therapy: A phase 2, multicenter, single-arm, open-label study","volume":"17","author":"Lu","year":"2022","journal-title":"J Thorac Oncol"},{"key":"key20250513102207_b23-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.medj.2024.02.011","article-title":"First-in-human phase I study of BEBT-109 in previously treated EGFR exon 20 insertion-mutated advanced non-small cell lung cancer","volume":"5","author":"Zeng","year":"2024","journal-title":"Med"},{"key":"key20250513102207_b24-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S2213-2600(23)00379-X","article-title":"Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): Single-arm, open-label, multicentre, phase 2 trial","volume":"12","author":"Wang","year":"2024","journal-title":"Lancet Respir Med"},{"key":"key20250513102207_b25-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"CT169","DOI":"10.1158\/1538-7445.AM2021-CT169","article-title":"Abstract CT169: Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC (ZENITH20-5)","volume":"81","author":"Le","year":"2021","journal-title":"Cancer Res"},{"key":"key20250513102207_b26-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1016\/j.jtho.2021.01.249","article-title":"MA11.04 updated efficacy, safety and dosing management of poziotinib in previously treated EGFR and HER2 exon 20 NSCLC patients","volume":"16","author":"Cornelissen","year":"2021","journal-title":"J Thorac Oncol"},{"key":"key20250513102207_b27-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.annonc.2021.01.051","article-title":"36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR\/HER2 Exon 20 mutant non-small cell lung cancer","volume":"32","author":"Sacher","year":"2021","journal-title":"Ann Oncol"},{"key":"key20250513102207_b28-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.ccell.2022.06.006","article-title":"Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity","volume":"40","author":"Elamin","year":"2022","journal-title":"Cancer Cell"},{"key":"key20250513102207_b29-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1200\/JCO.23.00152","article-title":"Safety, tolerability, and antitumor activity of zipalertinib among patients with non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions","volume":"41","author":"Piotrowska","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20250513102207_b30-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jtho.2023.09.1449","article-title":"Safety, tolerability, pharmacokinetics, and preliminary efficacy of YK-029A in treatment-naive patients with advanced NSCLC harboring EGFR exon 20 insertion mutations: A phase 1 trial","volume":"19","author":"Duan","year":"2024","journal-title":"J Thorac Oncol"},{"key":"key20250513102207_b31-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jtho.2023.09.033","article-title":"OA03.04 A phase 1b study of furmonertinib, an oral, brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR exon 20 insertions","volume":"18","author":"Han","year":"2023","journal-title":"J Thorac Oncol"},{"key":"key20250513102207_b32-ol-29-6-15062","first-page":"100558","article-title":"Real-world response and outcomes in patients with NSCLC with EGFR exon 20 insertion mutations","volume":"4","author":"Ou","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"key20250513102207_b33-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","article-title":"Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC","volume":"13","author":"Riess","year":"2018","journal-title":"J Thorac Oncol"},{"key":"key20250513102207_b34-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1080\/03007995.2022.2083326","article-title":"Non-small cell lung cancer with EGFR exon 20 insertion mutation: A systematic literature review and meta-analysis of patient outcomes","volume":"38","author":"Kwon","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"key20250513102207_b35-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12964-023-01082-8","article-title":"Toward the next generation EGFR inhibitors: An overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer","volume":"21","author":"Li","year":"2023","journal-title":"Cell Commun Signal"},{"key":"key20250513102207_b36-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1186\/s12885-019-5820-0","article-title":"EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer","volume":"19","author":"Fang","year":"2019","journal-title":"BMC Cancer"},{"key":"key20250513102207_b37-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"17588359221146131","DOI":"10.1177\/17588359221146131","article-title":"Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations","volume":"15","author":"Low","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"key20250513102207_b38-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.21037\/tcr.2020.03.10","article-title":"EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"9","author":"Wang","year":"2020","journal-title":"Transl Cancer Res"},{"key":"key20250513102207_b39-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1016\/j.cllc.2021.07.001","article-title":"EGFR exon 20 insertion NSCLC and response to platinum-based chemotherapy","volume":"23","author":"Shah","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"key20250513102207_b40-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"543","DOI":"10.21147\/j.issn.1000-9604.2017.06.09","article-title":"Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy","volume":"29","author":"Shi","year":"2017","journal-title":"Chin J Cancer Res"},{"key":"key20250513102207_b41-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.lungcan.2020.03.014","article-title":"EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study","volume":"145","author":"Yang","year":"2020","journal-title":"Lung Cancer"},{"key":"key20250513102207_b42-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.21037\/atm-20-6172","article-title":"Tumor genomics and response to chemotherapy in advanced non-small cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations","volume":"8","author":"Wang","year":"2020","journal-title":"Ann Transl Med"},{"key":"key20250513102207_b43-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2022","journal-title":"Genes Dis"},{"key":"key20250513102207_b44-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1200\/JCO.21.01323","article-title":"Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 trial","volume":"40","author":"Le","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20250513102207_b45-ol-29-6-15062","first-page":"87","article-title":"Top 20 EGFR+ NSCLC clinical and translational science papers that shaped the 20 years since the discovery of activating EGFR mutations in NSCLC. An editor-in-chief expert panel consensus survey","volume":"15","author":"Ou","year":"2024","journal-title":"Lung Cancer (Auckl)"},{"key":"key20250513102207_b46-ol-29-6-15062","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/actr-24-8","article-title":"YK-029A in the landscape of treatments for non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations","volume":"2","author":"Locke","year":"2024","journal-title":"AME Clin Trials Rev"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:22:16Z","timestamp":1747120936000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,28]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15062","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}